XML 152 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Segmentation of key figures - Top 20 (Details 9) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disclosure of operating segments [line items]      
Net sales to third parties $ 50,545 $ 51,626 $ 48,659
US      
Disclosure of operating segments [line items]      
Net sales to third parties 17,653 16,818 16,484
Innovative Medicines      
Disclosure of operating segments [line items]      
Net sales to third parties 41,296 41,995 39,013
Innovative Medicines | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 32,137 32,664 29,916
Innovative Medicines | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 9,159 9,331 9,097
Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,644 3,548 2,497
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,788 4,718 3,995
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,365 1,428 1,251
Innovative Medicines | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,133 1,059 873
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,013 2,787 3,003
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,370 1,351 920
Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,092    
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,770 1,693 1,542
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,231 937 687
Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     635
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,088 2,016 1,738
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,923 2,060 1,958
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,561 1,595 1,339
Innovative Medicines | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties   587  
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,874 2,160 1,933
Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties   584  
Innovative Medicines | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 536    
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,238 1,413 1,439
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 859 1,092 1,199
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 745 1,024 1,188
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 743 901 980
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 652 773 1,003
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 512 938 1,083
Innovative Medicines | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     653
Innovative Medicines | US      
Disclosure of operating segments [line items]      
Net sales to third parties 15,899 14,999 14,342
Innovative Medicines | US | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 12,753 11,688 11,126
Innovative Medicines | US | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 3,146 3,311 3,216
Innovative Medicines | US | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,354 1,712 1,277
Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,770 2,883 2,516
Innovative Medicines | US | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 570 501 400
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,153 1,427 1,562
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 434 469 459
Innovative Medicines | US | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 921    
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 678 606 569
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 472 339 318
Innovative Medicines | US | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     259
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,083 947 833
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 877 882 859
Innovative Medicines | US | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties   230  
Innovative Medicines | US | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 196    
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 800 843 837
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 205 263 315
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 14 14 16
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 55 51 124
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 171 521 644
Innovative Medicines | US | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     138
Innovative Medicines | Rest of the world [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 25,397 26,996 24,671
Innovative Medicines | Rest of the world [member] | Top 20 products [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 19,384 20,976 18,790
Innovative Medicines | Rest of the world [member] | Rest of portfolio [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 6,013 6,020 5,881
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Cardiovascular [member] | Top 20 products [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,290 1,836 1,220
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,018 1,835 1,479
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,365 1,428 1,251
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Immunology [member] | Top 20 products [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 563 558 473
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 860 1,360 1,441
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 936 882 461
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Neuroscience [member] | Top 20 products [member] | Kesimpta [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 171    
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,092 1,087 973
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 759 598 369
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Solid Tumors [member] | Top 20 products [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     376
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,005 1,069 905
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,046 1,178 1,099
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,561 1,595 1,339
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties   357  
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,874 2,160 1,933
Innovative Medicines | Rest of the world [member] | Promoted Brands [member] | Other Promoted Brands [member] | Top 20 products [member] | Ultibro Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties   584  
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Hematology [member] | Top 20 products [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 340    
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 438 570 602
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 859 1,092 1,199
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 540 761 873
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 729 887 964
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 597 722 879
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 341 417 439
Innovative Medicines | Rest of the world [member] | Established Brands [member] | Established Brands [member] | Top 20 products [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties     515
Operating segments [member] | Innovative Medicines | Promoted Brands [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 31,396 29,754 25,319
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,756 3,560 2,497
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Cardiovascular [member] | Entresto [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,644 3,548 2,497
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 7,287 7,205 6,119
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Cosentyx [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,788 4,718 3,995
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Xolair [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,365 1,428 1,251
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Immunology [member] | Ilaris [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,133 1,059 873
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 5,051 5,007 4,272
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Gilenya [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,013 2,787 3,003
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Zolgensma [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,370 1,351 920
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Neuroscience [member] | Kesimpta [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,092 372 15
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 4,723 4,101 3,666
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Tafinlar + Mekinist [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,770 1,693 1,542
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Kisqali [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,231 937 687
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Solid Tumors [member] | Votrient [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 474 577 635
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 6,452 6,430 5,617
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Promacta/Revolade [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 2,088 2,016 1,738
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Tasigna [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,923 2,060 1,958
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Jakavi [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,561 1,595 1,339
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Kymriah [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 536 587 474
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Hematology [member] | Adakveo [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 194 164 105
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 3,127 3,451 3,148
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Lucentis [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,874 2,160 1,933
Operating segments [member] | Innovative Medicines | Promoted Brands [member] | Other Promoted Brands [member] | Ultibro Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 479 584 623
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 9,900 12,241 13,694
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Sandostatin [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 1,238 1,413 1,439
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Galvus Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 859 1,092 1,199
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Gleevec/Glivec [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 745 1,024 1,188
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exforge Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 743 901 980
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Diovan Group [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 652 773 1,003
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Afinitor/Votubia [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 512 938 1,083
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Exjade/Jadenu [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 323 563 653
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Zortress/Certican [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 329 431 452
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Neoral/Sandimmun(e) [member]      
Disclosure of operating segments [line items]      
Net sales to third parties 310 368 393
Operating segments [member] | Innovative Medicines | Established Brands [member] | Established Brands [member] | Voltaren/Cataflam [member]      
Disclosure of operating segments [line items]      
Net sales to third parties $ 334 $ 373 $ 360